Brad Margus has recently raised $43 million and started Cerevance to advance new therapeutics for neurological and psychiatric diseases. In 2013, Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic and clinical data. From 2009 to 2012, as co-founder and CEO of Envoy Therapeutics, Margus raised $8 million from investors, discovered new compounds for brain diseases, and sold the company to a global pharmaceutical company for 15x invested capital. From 2000 to 2007, Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation.

Concurrent with his business career, for the last 20 years, Margus has worked as founder and volunteer President of the A-T Children’s Project, a non-profit that orchestrates research on a rare, brutal, genetic disease -- ataxia telangiectasia or "A-T" -- that two of his sons have. A-T causes neurodegeneration, cancer and immune system problems.

He also currently serves on the Boards of Second Genome, a microbiome company; Arvinas, a protein degradation and cancer company; and Presage Biosciences, a cancer company. He continues to serve as a Harvard Business School Global Advisor and as a member of three National Institutes of Health committees: the National Center for Advancing Translational Sciences Advisory Council, the Cure Acceleration Network Review Board, and as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board. He also sits on the Board of Global Genes, a non-profit organization that supports advocates for all rare diseases.